{"title":"Effects of Drugs and Chemotherapeutic Agents on Dental Implant Osseointegration: A Narrative Review.","authors":"Aida Mohammadi, Nazanin Roqani Dehkordi, Sadaf Mahmoudi, Niyousha Rafeie, Hamoun Sabri, Maryam Valizadeh, Taniya Poorsoleiman, Aryan Jafari, Alireza Mokhtari, Arshia Khanjarani, Yasaman Salimi, Melika Mokhtari, Niloofar Deravi","doi":"10.2174/2772432817666220607114559","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Dental implants have been one of the most popular treatments for rehabilitating individuals with single missing teeth or fully edentulous jaws since their introduction. As more implant patients are well-aged and take several medications due to various systemic conditions, clinicians should take into consideration the possible drug implications on bone remodeling and osseointegration.</p><p><strong>Objective: </strong>The present study aims to examine and review some desirable and unwelcomed implications of medicine on osseointegration.</p><p><strong>Methods: </strong>A broad search for proper relevant studies was conducted in four databases, including Web of Science, Pubmed, Scopus, and Google Scholar.</p><p><strong>Results: </strong>Some commonly prescribed medicines, such as nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, proton pump inhibitors (PPIs), selective serotonin reuptake inhibitors (SSRIs), anticoagulants, metformin, and chemotherapeutic agents, may jeopardize osseointegration. On the contrary, some therapeutic agents, such as anabolic, anti-catabolic, or dual anabolic agents may enhance osseointegration and increase the treatment's success rate.</p><p><strong>Conclusion: </strong>Systemic medications that enhance osseointegration include mineralization promoters and bone resorption inhibitors. On the other hand, medications often given to the elderly with systemic problems might interfere with osseointegration, leading to implant failure. However, to validate the research, more human studies with a higher level of evidence are required.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":" ","pages":"42-60"},"PeriodicalIF":17.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2772432817666220607114559","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Dental implants have been one of the most popular treatments for rehabilitating individuals with single missing teeth or fully edentulous jaws since their introduction. As more implant patients are well-aged and take several medications due to various systemic conditions, clinicians should take into consideration the possible drug implications on bone remodeling and osseointegration.
Objective: The present study aims to examine and review some desirable and unwelcomed implications of medicine on osseointegration.
Methods: A broad search for proper relevant studies was conducted in four databases, including Web of Science, Pubmed, Scopus, and Google Scholar.
Results: Some commonly prescribed medicines, such as nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, proton pump inhibitors (PPIs), selective serotonin reuptake inhibitors (SSRIs), anticoagulants, metformin, and chemotherapeutic agents, may jeopardize osseointegration. On the contrary, some therapeutic agents, such as anabolic, anti-catabolic, or dual anabolic agents may enhance osseointegration and increase the treatment's success rate.
Conclusion: Systemic medications that enhance osseointegration include mineralization promoters and bone resorption inhibitors. On the other hand, medications often given to the elderly with systemic problems might interfere with osseointegration, leading to implant failure. However, to validate the research, more human studies with a higher level of evidence are required.
背景自种植牙问世以来，种植牙一直是修复单颗缺失牙齿或完全无牙颌患者最受欢迎的治疗方法之一。由于越来越多的植入物患者年龄较大，由于各种系统性疾病需要服用多种药物，临床医生应注意药物对骨重塑和骨整合的可能影响。目的本研究旨在研究和回顾医学在骨整合方面的一些可取和不可取的意义。方法在包括Web of Science、Pubmed、Scopus和Google Scholar在内的四个数据库中广泛搜索适当的相关研究。结果一些常用药物，如非甾体抗炎药（NSAIDs）、糖皮质激素、质子泵抑制剂（PPIs）、选择性血清素再摄取抑制剂（SSRIs）、抗凝血剂、二甲双胍和化疗药物，可能会危及骨整合。相反，一些治疗药物，如合成代谢、抗分解代谢或合成代谢和抗分解代谢双重药物，可以增强骨整合并提高治疗的成功率。结论增强骨整合的系统性药物包括矿化促进剂和骨吸收抑制剂。另一方面，经常给有系统问题的老年人服用的药物可能会干扰骨整合，导致植入失败。然而，为了验证所提供的研究，需要更多具有更高证据水平的人类研究。
期刊介绍：
Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance.
Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
